202 related articles for article (PubMed ID: 35579144)
21. Medulloblastoma: WHO 2021 and Beyond.
Cotter JA; Hawkins C
Pediatr Dev Pathol; 2022; 25(1):23-33. PubMed ID: 35168417
[TBL] [Abstract][Full Text] [Related]
22. Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K; Taylor MD
J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
[TBL] [Abstract][Full Text] [Related]
23. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
24. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
25. Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases.
Pizem J; Popovic M; Cör A
J Neurooncol; 2011 Jul; 103(3):459-67. PubMed ID: 20953661
[TBL] [Abstract][Full Text] [Related]
26. The proteomic analysis shows enrichment of RNA surveillance pathways in adult SHH and extensive metabolic reprogramming in Group 3 medulloblastomas.
Kp M; Kumar A; Biswas D; Moiyadi A; Shetty P; Gupta T; Epari S; Shirsat N; Srivastava S
Brain Tumor Pathol; 2021 Apr; 38(2):96-108. PubMed ID: 33438046
[TBL] [Abstract][Full Text] [Related]
27. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
Menyhárt O; Győrffy B
Cancer Metastasis Rev; 2020 Mar; 39(1):211-233. PubMed ID: 31970590
[TBL] [Abstract][Full Text] [Related]
28. Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.
Moreno DA; da Silva LS; Zanon MF; Bonatelli M; de Paula FE; de Medeiros Matsushita M; Teixeira GR; Santana IVV; Saggioro F; Neder L; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Garcia-Rivello H; Christiansen S; Nunes S; da Costa MJG; Soares MJ; Pinheiro J; Junior CA; Mançano BM; Reis RM
J Neurooncol; 2022 Mar; 157(1):27-35. PubMed ID: 35166989
[TBL] [Abstract][Full Text] [Related]
29. Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets.
Marques RF; Moreno DA; da Silva L; Leal LF; de Paula FE; Santana I; Teixeira G; Saggioro F; Neder L; Junior CA; Mançano B; Reis RM
Front Immunol; 2023; 14():1062856. PubMed ID: 36825029
[TBL] [Abstract][Full Text] [Related]
30. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.
Menyhárt O; Giangaspero F; Győrffy B
J Hematol Oncol; 2019 Mar; 12(1):29. PubMed ID: 30876441
[TBL] [Abstract][Full Text] [Related]
31. Signaling pathway deregulation and molecular alterations across pediatric medulloblastomas.
Lhermitte B; Blandin AF; Coca A; Guerin E; Durand A; Entz-Werlé N
Neurochirurgie; 2021 Feb; 67(1):39-45. PubMed ID: 29776650
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Drivers in Pediatric Medulloblastoma.
Roussel MF; Stripay JL
Cerebellum; 2018 Feb; 17(1):28-36. PubMed ID: 29178021
[TBL] [Abstract][Full Text] [Related]
33. Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.
Vaillant C; Valdivieso P; Nuciforo S; Kool M; Schwarzentruber-Schauerte A; Méreau H; Cabuy E; Lobrinus JA; Pfister S; Zuniga A; Frank S; Zeller R
PLoS One; 2015; 10(4):e0124870. PubMed ID: 25901736
[TBL] [Abstract][Full Text] [Related]
34. Roles and interactions of tumor microenvironment components in medulloblastoma with implications for novel therapeutics.
Yang H; Li M; Deng Y; Wen H; Luo M; Zhang W
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23233. PubMed ID: 38607297
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
Archer TC; Mahoney EL; Pomeroy SL
Neurotherapeutics; 2017 Apr; 14(2):265-273. PubMed ID: 28386677
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.
Bharambe HS; Paul R; Panwalkar P; Jalali R; Sridhar E; Gupta T; Moiyadi A; Shetty P; Kazi S; Deogharkar A; Masurkar S; Yogi K; Kunder R; Gadewal N; Goel A; Goel N; Chinnaswamy G; Ramaswamy V; Shirsat NV
Acta Neuropathol Commun; 2019 Apr; 7(1):52. PubMed ID: 30944042
[TBL] [Abstract][Full Text] [Related]
37. Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas.
Harter PN; Baumgarten P; Zinke J; Schilling K; Baader S; Hartmetz AK; Schittenhelm J; Beschorner R; Liebner S; Schulte D; Plate KH; Gutwein P; Korshunov A; Pfister SM; Jones DT; Doberstein K; Mittelbronn M
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):165-79. PubMed ID: 25287489
[TBL] [Abstract][Full Text] [Related]
38. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
39. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
40. Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts.
Leskoske KL; Garcia-Mansfield K; Sharma R; Krishnan A; Rusert JM; Mesirov JP; Wechsler-Reya RJ; Pirrotte P
J Proteome Res; 2022 Sep; 21(9):2124-2136. PubMed ID: 35977718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
